SG Americas Securities LLC lessened its position in Novartis AG (NYSE:NVS – Free Report) by 51.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,348 shares of the company’s stock after selling 10,948 shares during the quarter. SG Americas Securities LLC’s holdings in Novartis were worth $1,007,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Steigerwald Gordon & Koch Inc. increased its position in shares of Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. grew its stake in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after buying an additional 98 shares in the last quarter. FLC Capital Advisors increased its holdings in Novartis by 4.4% during the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after buying an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC raised its position in Novartis by 2.3% during the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after acquiring an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC lifted its stake in Novartis by 1.8% in the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock valued at $666,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.
Novartis Stock Performance
Shares of NVS stock opened at $101.85 on Wednesday. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The firm has a 50-day moving average of $100.10 and a 200-day moving average of $108.64. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The company has a market cap of $208.19 billion, a P/E ratio of 11.83, a P/E/G ratio of 1.42 and a beta of 0.57.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets increased their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $123.38.
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
- Five stocks we like better than Novartis
- Differences Between Momentum Investing and Long Term Investing
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- 5 discounted opportunities for dividend growth investors
- What Does the Future Hold for Eli Lilly?
- Insider Trades May Not Tell You What You Think
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.